Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 136

1.

Longitudinal analysis of contrast acuity in Friedreich ataxia.

Hamedani AG, Hauser LA, Perlman S, Mathews K, Wilmot GR, Zesiewicz T, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Lynch DR.

Neurol Genet. 2018 Jul 23;4(4):e250. doi: 10.1212/NXG.0000000000000250. eCollection 2018 Aug.

2.

Double-blind, randomized and controlled trial of EPI-743 in Friedreich's ataxia.

Zesiewicz T, Salemi JL, Perlman S, Sullivan KL, Shaw JD, Huang Y, Isaacs C, Gooch C, Lynch DR, Klein MB.

Neurodegener Dis Manag. 2018 Aug;8(4):233-242. doi: 10.2217/nmt-2018-0013. Epub 2018 Jul 27.

PMID:
30051753
3.

Strong correlations among four measures of disease progression in Friedreich's ataxia.

Saal HJ, Heerinckx F, Zawadzki R, Omidvar O, Kilpatrick M, Zesiewicz T.

Mov Disord. 2018 Jul;33(6):1021-1022. doi: 10.1002/mds.27351. Epub 2018 Apr 6. No abstract available.

PMID:
29624733
4.

Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxia.

Zesiewicz T, Heerinckx F, De Jager R, Omidvar O, Kilpatrick M, Shaw J, Shchepinov MS.

Mov Disord. 2018 Jul;33(6):1000-1005. doi: 10.1002/mds.27353. Epub 2018 Apr 6.

PMID:
29624723
5.

Impact of Mobility Device Use on Quality of Life in Children With Friedreich Ataxia.

Ejaz R, Chen S, Isaacs CJ, Carnevale A, Wilson J, George K, Delatycki MB, Perlman SL, Mathews KD, Wilmot GR, Hoyle JC, Subramony SH, Zesiewicz T, Farmer JM, Lynch DR, Yoon G.

J Child Neurol. 2018 May;33(6):397-404. doi: 10.1177/0883073818764941. Epub 2018 Apr 2.

PMID:
29607705
6.

Comprehensive systematic review summary: Treatment of cerebellar motor dysfunction and ataxia: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Zesiewicz TA, Wilmot G, Kuo SH, Perlman S, Greenstein PE, Ying SH, Ashizawa T, Subramony SH, Schmahmann JD, Figueroa KP, Mizusawa H, Schöls L, Shaw JD, Dubinsky RM, Armstrong MJ, Gronseth GS, Sullivan KL.

Neurology. 2018 Mar 6;90(10):464-471. doi: 10.1212/WNL.0000000000005055. Epub 2018 Feb 9.

PMID:
29440566
7.

C9orf72 repeat expansions as genetic modifiers for depression in spinocerebellar ataxias.

Figueroa KP, Gan SR, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Pulst SM, Kuo SH.

Mov Disord. 2018 Mar;33(3):497-498. doi: 10.1002/mds.27258. Epub 2017 Nov 29. No abstract available.

PMID:
29193335
8.

Dystonia and ataxia progression in spinocerebellar ataxias.

Kuo PH, Gan SR, Wang J, Lo RY, Figueroa KP, Tomishon D, Pulst SM, Perlman S, Wilmot G, Gomez CM, Schmahmann JD, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Parkinsonism Relat Disord. 2017 Dec;45:75-80. doi: 10.1016/j.parkreldis.2017.10.007. Epub 2017 Oct 23.

9.

Postural Tremor and Ataxia Progression in Spinocerebellar Ataxias.

Gan SR, Wang J, Figueroa KP, Pulst SM, Tomishon D, Lee D, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind MD, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2017 Oct 9;7:492. doi: 10.7916/D8GM8KRH. eCollection 2017.

10.

Impact of diabetes in the Friedreich ataxia clinical outcome measures study.

McCormick A, Farmer J, Perlman S, Delatycki M, Wilmot G, Matthews K, Yoon G, Hoyle C, Subramony SH, Zesiewicz T, Lynch DR, McCormack SE.

Ann Clin Transl Neurol. 2017 Jul 26;4(9):622-631. doi: 10.1002/acn3.439. eCollection 2017 Sep.

11.

Quality improvement in neurology: Essential Tremor Quality Measurement Set.

Zesiewicz TA, Sullivan KL, Ponce de Leon M, Bennett A, Hohler AD.

Neurology. 2017 Sep 19;89(12):1291-1295. doi: 10.1212/WNL.0000000000004372. Epub 2017 Aug 23. No abstract available.

PMID:
28835402
12.

Longitudinal gait and balance decline in Friedreich's Ataxia: A pilot study.

Zesiewicz TA, Stephenson JB, Kim SH, Sullivan KL, Jahan I, Huang Y, Salemi JL, Wecker L, Shaw JD, Gooch CL.

Gait Posture. 2017 Jun;55:25-30. doi: 10.1016/j.gaitpost.2017.03.019. Epub 2017 Mar 30.

PMID:
28411441
13.

A randomized, fixed-dose, dose-response study of ropinirole prolonged release in advanced Parkinson's disease.

Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, Davy M, VanMeter S.

Neurodegener Dis Manag. 2017 Feb;7(1):61-72. doi: 10.2217/nmt-2016-0038. Epub 2017 Jan 25.

14.

A fixed-dose, dose-response study of ropinirole prolonged release in early stage Parkinson's disease.

Zesiewicz TA, Chriscoe S, Jimenez T, Upward J, VanMeter S.

Neurodegener Dis Manag. 2017 Feb;7(1):49-59. doi: 10.2217/nmt-2016-0039. Epub 2017 Jan 25.

15.

Practice guideline summary: Treatment of restless legs syndrome in adults: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology.

Winkelman JW, Armstrong MJ, Allen RP, Chaudhuri KR, Ondo W, Trenkwalder C, Zee PC, Gronseth GS, Gloss D, Zesiewicz T.

Neurology. 2016 Dec 13;87(24):2585-2593. Epub 2016 Nov 16.

16.

The Initial Symptom and Motor Progression in Spinocerebellar Ataxias.

Luo L, Wang J, Lo RY, Figueroa KP, Pulst SM, Kuo PH, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Cerebellum. 2017 Jun;16(3):615-622. doi: 10.1007/s12311-016-0836-3.

17.

Progression of Friedreich ataxia: quantitative characterization over 5 years.

Patel M, Isaacs CJ, Seyer L, Brigatti K, Gelbard S, Strawser C, Foerster D, Shinnick J, Schadt K, Yiu EM, Delatycki MB, Perlman S, Wilmot GR, Zesiewicz T, Mathews K, Gomez CM, Yoon G, Subramony SH, Brocht A, Farmer J, Lynch DR.

Ann Clin Transl Neurol. 2016 Jul 25;3(9):684-94. doi: 10.1002/acn3.332. eCollection 2016 Sep.

18.

Comorbid Medical Conditions in Friedreich Ataxia: Association With Inflammatory Bowel Disease and Growth Hormone Deficiency.

Shinnick JE, Schadt K, Strawser C, Wilcox N, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Yiu EM, Delatycki MB, Brocht AF, Farmer JM, Lynch DR.

J Child Neurol. 2016 Aug;31(9):1161-5. doi: 10.1177/0883073816643408. Epub 2016 Apr 12.

PMID:
27071470
19.

Emerging therapies in Friedreich's ataxia.

Aranca TV, Jones TM, Shaw JD, Staffetti JS, Ashizawa T, Kuo SH, Fogel BL, Wilmot GR, Perlman SL, Onyike CU, Ying SH, Zesiewicz TA.

Neurodegener Dis Manag. 2016;6(1):49-65. doi: 10.2217/nmt.15.73. Review.

20.

Essential tremor.

Zesiewicz TA, Kuo SH.

BMJ Clin Evid. 2015 Dec 15;2015. pii: 1206.

21.

Depression and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Yu JT, Lee LE, Ashizawa T, Subramony SH, Kuo SH.

Parkinsonism Relat Disord. 2016 Jan;22:87-92. doi: 10.1016/j.parkreldis.2015.11.021. Epub 2015 Nov 22.

22.

A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson's Disease-Associated Chronic Pain.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L.

J Clin Pharmacol. 2016 Jul;56(7):852-61. doi: 10.1002/jcph.678. Epub 2015 Dec 31.

PMID:
26626320
23.

Occupational Characteristics and Patterns as Risk Factors for Parkinson's Disease: A Case Control Study.

Sullivan KL, Mortimer JA, Wang W, Zesiewicz TA, Brownlee HJ, Borenstein AR.

J Parkinsons Dis. 2015;5(4):813-20. doi: 10.3233/JPD-150635.

PMID:
26444091
24.

Frataxin levels in peripheral tissue in Friedreich ataxia.

Lazaropoulos M, Dong Y, Clark E, Greeley NR, Seyer LA, Brigatti KW, Christie C, Perlman SL, Wilmot GR, Gomez CM, Mathews KD, Yoon G, Zesiewicz T, Hoyle C, Subramony SH, Brocht AF, Farmer JM, Wilson RB, Deutsch EC, Lynch DR.

Ann Clin Transl Neurol. 2015 Aug;2(8):831-42. doi: 10.1002/acn3.225. Epub 2015 Jul 1.

25.

Plasma Derived From Human Umbilical Cord Blood Modulates Mitogen-Induced Proliferation of Mononuclear Cells Isolated From the Peripheral Blood of ALS Patients.

Eve DJ, Ehrhart J, Zesiewicz T, Jahan I, Kuzmin-Nichols N, Sanberg CD, Gooch C, Sanberg PR, Garbuzova-Davis S.

Cell Transplant. 2016;25(5):963-71. doi: 10.3727/096368915X688579. Epub 2015 Jul 8.

PMID:
26159164
26.

Humoral factors in ALS patients during disease progression.

Ehrhart J, Smith AJ, Kuzmin-Nichols N, Zesiewicz TA, Jahan I, Shytle RD, Kim SH, Sanberg CD, Vu TH, Gooch CL, Sanberg PR, Garbuzova-Davis S.

J Neuroinflammation. 2015 Jun 28;12:127. doi: 10.1186/s12974-015-0350-4.

27.

Clinically meaningful parameters of progression and long-term outcome of Parkinson disease: An international consensus statement.

Puschmann A, Brighina L, Markopoulou K, Aasly J, Chung SJ, Frigerio R, Hadjigeorgiou G, Kõks S, Krüger R, Siuda J, Wider C, Zesiewicz TA, Maraganore DM.

Parkinsonism Relat Disord. 2015 Jul;21(7):675-82. doi: 10.1016/j.parkreldis.2015.04.029. Epub 2015 May 1. Review.

PMID:
25952959
28.

Randomized, controlled pilot trial of solifenacin succinate for overactive bladder in Parkinson's disease.

Zesiewicz TA, Evatt M, Vaughan CP, Jahan I, Singer C, Ordorica R, Salemi JL, Shaw JD, Sullivan KL; Non-Motor Working Group of the Parkinson Study Group (PSG).

Parkinsonism Relat Disord. 2015 May;21(5):514-20. doi: 10.1016/j.parkreldis.2015.02.025. Epub 2015 Mar 6.

PMID:
25814050
29.

Vascular risk factors and clinical progression in spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez CM, Schmahmann J, Paulson H, Shakkottai VG, Ying SH, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 2;5:287. doi: 10.7916/D89885S0. eCollection 2015.

30.

Gait and balance in adults with Friedreich's ataxia.

Stephenson J, Zesiewicz T, Gooch C, Wecker L, Sullivan K, Jahan I, Kim SH.

Gait Posture. 2015 Feb;41(2):603-7. doi: 10.1016/j.gaitpost.2015.01.002. Epub 2015 Jan 8.

PMID:
25662043
31.

Coenzyme Q10 and spinocerebellar ataxias.

Lo RY, Figueroa KP, Pulst SM, Lin CY, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai VG, Ying S, Zesiewicz T, Bushara K, Geschwind M, Xia G, Subramony SH, Ashizawa T, Kuo SH.

Mov Disord. 2015 Feb;30(2):214-20. doi: 10.1002/mds.26088. Epub 2014 Dec 1.

32.

Medical marijuana in neurology.

Benbadis SR, Sanchez-Ramos J, Bozorg A, Giarratano M, Kalidas K, Katzin L, Robertson D, Vu T, Smith A, Zesiewicz T.

Expert Rev Neurother. 2014 Dec;14(12):1453-65. doi: 10.1586/14737175.2014.985209. Review.

PMID:
25427150
33.

Treatment of cerebellar ataxia.

Jones TM, Shaw JD, Sullivan K, Zesiewicz TA.

Neurodegener Dis Manag. 2014;4(5):379-92. doi: 10.2217/nmt.14.27. Review.

PMID:
25405651
34.

Clinical evaluation of eye movements in spinocerebellar ataxias: a prospective multicenter study.

Moscovich M, Okun MS, Favilla C, Figueroa KP, Pulst SM, Perlman S, Wilmot G, Gomez C, Schmahmann J, Paulson H, Shakkottai V, Ying S, Zesiewicz T, Kuo SH, Mazzoni P, Bushara K, Xia G, Ashizawa T, Subramony SH.

J Neuroophthalmol. 2015 Mar;35(1):16-21. doi: 10.1097/WNO.0000000000000167.

35.

Autologous stem cell transplant with gene therapy for Friedreich ataxia.

Tajiri N, Staples M, Kaneko Y, Kim SU, Zesiewicz TA, Borlongan CV.

Med Hypotheses. 2014 Sep;83(3):296-8. doi: 10.1016/j.mehy.2014.05.022. Epub 2014 Jun 9.

36.

Author response.

Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2014 Feb 18;82(7):643. No abstract available.

PMID:
24745039
37.

Rotigotine transdermal system and evaluation of pain in patients with Parkinson's disease: a post hoc analysis of the RECOVER study.

Kassubek J, Chaudhuri KR, Zesiewicz T, Surmann E, Boroojerdi B, Moran K, Ghys L, Trenkwalder C.

BMC Neurol. 2014 Mar 6;14:42. doi: 10.1186/1471-2377-14-42.

38.

Unusual wrist tremor: unilateral isometric tremor?

Zesiewicz T, Vu T, Carranza MA, Appelbaum R, Snyder M, Staffetti JS, Allison KG, Shimberg WR, Louis ED.

Tremor Other Hyperkinet Mov (N Y). 2014 Jan 8;4. pii: tre-04-194-4738-1. doi: 10.7916/D8445K5T. eCollection 2014 Jan 8.

39.

Author response.

Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2013 Nov 26;81(22):1967. No abstract available.

PMID:
24416785
40.

Evidence-based guideline: Treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Lerner V, Miodownik C, Sheva B, Bhidayasiri R, Fahn S, Gronseth GS, Sullivan KL, Zesiewicz TA.

Neurology. 2013 Nov 26;81(22):1967. doi: 10.1212/01.wnl.0000439053.82390.26. No abstract available.

PMID:
24276337
41.

Effects of rotigotine transdermal system on non-motor symptoms in Parkinson's disease: an overview.

Zesiewicz TA, Martinez-Martin P.

Expert Rev Neurother. 2013 Dec;13(12):1329-42. doi: 10.1586/14737175.2013.859986. Review.

PMID:
24236902
42.

Clinical characteristics of patients with spinocerebellar ataxias 1, 2, 3 and 6 in the US; a prospective observational study.

Ashizawa T, Figueroa KP, Perlman SL, Gomez CM, Wilmot GR, Schmahmann JD, Ying SH, Zesiewicz TA, Paulson HL, Shakkottai VG, Bushara KO, Kuo SH, Geschwind MD, Xia G, Mazzoni P, Krischer JP, Cuthbertson D, Holbert AR, Ferguson JH, Pulst SM, Subramony SH.

Orphanet J Rare Dis. 2013 Nov 13;8:177. doi: 10.1186/1750-1172-8-177.

43.

Randomized trial of cognitive speed of processing training in Parkinson disease.

Edwards JD, Hauser RA, O'Connor ML, Valdés EG, Zesiewicz TA, Uc EY.

Neurology. 2013 Oct 8;81(15):1284-90. doi: 10.1212/WNL.0b013e3182a823ba. Epub 2013 Sep 6.

44.

Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology.

Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA; American Academy of Neurology.

Neurology. 2013 Jul 30;81(5):463-9. doi: 10.1212/WNL.0b013e31829d86b6. Review. Erratum in: Neurology. 2013 Nov 26;81(22):1968.

PMID:
23897874
45.

Update on treatment of essential tremor.

Zesiewicz TA, Shaw JD, Allison KG, Staffetti JS, Okun MS, Sullivan KL.

Curr Treat Options Neurol. 2013 Aug;15(4):410-23. doi: 10.1007/s11940-013-0239-4.

PMID:
23881742
46.

Analysis of the visual system in Friedreich ataxia.

Seyer LA, Galetta K, Wilson J, Sakai R, Perlman S, Mathews K, Wilmot GR, Gomez CM, Ravina B, Zesiewicz T, Bushara KO, Subramony SH, Ashizawa T, Delatycki MB, Brocht A, Balcer LJ, Lynch DR.

J Neurol. 2013 Sep;260(9):2362-9. doi: 10.1007/s00415-013-6978-z. Epub 2013 Jun 18.

PMID:
23775342
47.

Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia.

Wecker L, Engberg ME, Philpot RM, Lambert CS, Kang CW, Antilla JC, Bickford PC, Hudson CE, Zesiewicz TA, Rowell PP.

Neuropharmacology. 2013 Oct;73:75-86. doi: 10.1016/j.neuropharm.2013.05.016. Epub 2013 May 24.

48.

Sustained Medication Reduction Following Unilateral VIM Thalamic Stimulation for Essential Tremor.

Resnick AS, Okun MS, Malapira T, Smith D, Vale FL, Sullivan K, Miller A, Jahan I, Zesiewicz T.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-38-193-1. doi: 10.7916/D8ZG6QZ2. Epub 2012 Apr 6.

49.

Methodological issues in clinical drug development for essential tremor.

Carranza MA, Snyder MR, Elble RJ, Boutzoukas AE, Zesiewicz TA.

Tremor Other Hyperkinet Mov (N Y). 2012;2. pii: tre-02-68-402-1. doi: 10.7916/D8P55M7F. Epub 2012 Aug 6.

50.

Multisite, double-blind, randomized, controlled study of pregabalin for essential tremor.

Zesiewicz TA, Sullivan KL, Hinson V, Stover NP, Fang J, Jahan I, Miller A, Carranza MA, Elble R.

Mov Disord. 2013 Feb;28(2):249-50. doi: 10.1002/mds.25264. Epub 2012 Dec 12. No abstract available.

PMID:
23238907

Supplemental Content

Loading ...
Support Center